$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
HER2阳性乳腺癌服用来那替尼联合T-DM1可获得60%的生存期
2025-10-19 11:44:20
Check Details
奥拉帕尼的疗效比化疗的疗效高出两倍有余
2025-10-19 11:44:20
Check Details
服用奥拉帕尼前后需要注意什么事项?
2025-10-19 11:44:20
Check Details
BRCA突变乳腺癌服用奥拉帕尼治疗有效率高达85%
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗卵巢癌之前基因检测的重要性
2025-10-19 11:44:20
Check Details
乳腺癌患者服用奥拉帕尼可使疾病不恶化时间延至更长
2025-10-19 11:44:20
Check Details
奥拉帕尼获批治疗BRCA突变的乳腺癌患者
2025-10-19 11:44:20
Check Details
妊娠期可以服用奥拉帕尼吗?
2025-10-19 11:44:20
Check Details
奥拉帕尼获批治疗转移性乳腺癌
2025-10-19 11:44:20
Check Details
遗传性乳腺癌服用奥拉帕尼效果如何?
2025-10-19 11:44:20
Check Details
孕妇及哺乳期妇女可以服用奥拉帕尼吗?
2025-10-19 11:44:20
Check Details
帕博西林与来曲唑联合治疗晚期乳腺癌
2025-10-19 11:44:20
Check Details
1
2
...
7705
7706
7707
7708
7709
7710
7711
...
10214
10215
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Niraparib: A PARP Inhibitor for Ovarian Cancer Maintenance Therapy
2
Abiraterone Acetate: CYP17 Inhibitor for Advanced Prostate Cancer
3
Plerixafor: Mobilizing Hematopoietic Stem Cells for Autologous Transplantation
4
Brensoctib: Managing Side Effects of the Novel DPP-1 Inhibitor for Bronchiectasis
5
Tivozanib: The Evolution of Highly Selective VEGFR Inhibition in Renal Cell Carcinoma
6
Trifluridine/Tipiracil: Managing Side Effects in Metastatic Colorectal and Gastric Cancer
7
Trelagliptin: The First Once-Weekly DPP-4 Inhibitor Revolutionizing Type 2 Diabetes Care
8
Adagrasib Medication Management Guide for Special Populations
9
Olutasidenib (Rezlidhia): A Targeted Drug for IDH1-Mutated Relapsed/Refractory AML
10
Capmatinib Redefines Precision Therapy for MET-Mutated Lung Cancer
11
FDA Approves Dual Immunotherapy Combo: Tecvayli + Darzalex Faspro Transforms RRMM Treatment
12
Cabozantinib: Pivotal Advancements and Global Implications in Multi-Cancer Treatment with Multi-Kinase Inhibition